AbbVie
ABBV
#25
Rank
NZ$920.97 B
Marketcap
NZ$521.02
Share price
-2.33%
Change (1 day)
26.08%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

Market capitalization of AbbVie (ABBV)

Market cap: NZ$920.97 Billion

As of November 2026 AbbVie has a market cap of NZ$920.97 Billion. This makes AbbVie the world's 25th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.

Market cap history of AbbVie from 2012 to 2026

End of year Market Cap

Year Marketcap Change
2026NZ$920.97 B31.22%
2025NZ$701.82 B25.83%
2024NZ$557.77 B28.92%
2023NZ$432.64 B-3.89%
2022NZ$450.15 B28.45%
2021NZ$350.44 B33.67%
2020NZ$262.17 B34.84%
2019NZ$194.42 B-4.34%
2018NZ$203.24 B-6.51%
2017NZ$217.38 B47.97%
2016NZ$146.91 B5.43%
2015NZ$139.34 B4.84%
2014NZ$132.91 B30.29%
2013NZ$102.01 B55.48%
2012NZ$65.60 B

End of Day market cap according to different sources

On Nov 18th, 2026 the market cap of AbbVie was reported to be:

NZ$920.90 Billion
by Nasdaq info icon info icon
NZ$920.97 Billion
by CompaniesMarketCap info icon info icon

Market capitalization for similar companies or competitors

Name Marketcap Market cap differencediff. Country
Pfizer
PFE
NZ$291.35 B-68.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$2.243 T 143.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$437.39 B-52.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$67.70 B-92.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$381.81 B-58.54%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$221.78 B-75.92%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$505.05 B-45.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$177.39 B-80.74%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$30.02 B-96.74%๐Ÿ‡บ๐Ÿ‡ธ USA